Bristol-Myers Squibb Company (BMY) New York Stock Exchange
49.721.753.65%
CloseJanuary 15, 2019

News: updated – 16-Jan 01:33


The Best Dividend Stocks You Can Buy Today15-Jan 05:10(SeekingAlpha)

(Source: imgflip ) Note that due to reader requests, I’ve decided to break up my weekly portfolio updates into three parts: commentary, economic update, and the new "best stocks to buy right now" series. This is to avoid excessively long articles and maximize the utility to my readers. …

M&A Updates: CVC Capital Is Interested In French Insurer April SA15-Jan 03:25(SeekingAlpha)

Mid Atlantic Dental Partners have closed the acquisition of Birner Dental( OTC:BDMS ) and brought 4.6% profit in 2 months + 1% still potentially coming from the CVR. Another mining deal ( previous article ) between Pan American Silver( PAAS )/Tahoe Resources( TAHO ) has also received…

Gritstone Oncology: A Hope For Cancer Patients But Not For Value Investors Yet15-Jan 03:10(SeekingAlpha)

This is a gritstone on the company’s website. Summary If you are holding it, sell. If not, invest accordingly when 2H19 IND data released for GRANITE-001 but expect the worst case scenario when the company might drop to $4 per share, which is the net cash value, assuming all the pipeline p…

3 Reasons Bristol-Myers’ $90 Billion Mega-Merger Makes It A Must Own Stock15-Jan 02:45(SeekingAlpha)

(Source: imgflip ) There’s nothing like the worst correction in a decade to put great dividend growth stocks on sale. That’s especially true when industry/company specific news combines to create a perfect storm of negativity that makes for truly sensational bargains of even the highest-qua…

Bristol-Myers Squibb Stock Issued For Celgene: I Plan To Keep It15-Jan 02:28(SeekingAlpha)

Bristol-Myers Squibb ( BMY ) is buying Celgene ( CELG ), with the deal likely to close in Q3. I do not own BMY stock, though I have looked at that possibility on occasion. A substantial amount of my portfolio is Celgene stock. In this story I will examine whether I should keep the BMY stock I …

Bristol-Myers gets two-notch upgrade post-Celgene deal15-Jan 01:28(SeekingAlpha)

ScoGen was previously the only sell-side shop with a Sell rating on Bristol-Myers Squibb (NYSE: BMY ), but is a big fan of the Celgene (NASDAQ: CELG ) acquisition, and upgrades all the way to Buy. More news on: Bristol-Myers Squibb Company, Celgene Corporation, Healthcare stocks news, Stoc…

FDA to beef up cell and gene therapy staff15-Jan 01:17(SeekingAlpha)

Citing the 800 active INDs for cell therapy and gene therapy candidates and the expectation that it will be receiving more that 200 INDs each year by 2020, FDA Commission Scott Gottlieb, M.D., outlines the agency’s initiatives to support timely review and to enable the approval of 10 – 20 …

FDA Commish touts advances/successes15-Jan 12:45(SeekingAlpha)

In a stream of tweets , FDA Commissioner Scott Gottlieb, M.D. details a number of accomplishments and advances by the agency. Highlights: More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & Wellness Rx Trust, Tekla World Healthcare Fund, Healthcare stocks …

Merger Arbitrage Mondays – January 14, 201814-Jan 07:56(SeekingAlpha)

Merger activity increased last week with three new deals announced and seven pending deals closing. Deal Statistics: New Deals: The acquisition of Luxoft Holding (LXFT) by DXC Technology Company (DXC) for $2 billion or $59.00 per share in cash. The acquisition of Loxo Oncolo…